法国2012-2020年肺外脓肿分枝杆菌感染研究
该研究回顾性分析了法国2012-2020年45例微生物学确诊的肺外脓肿分枝杆菌感染病例,其中62%无免疫缺陷,27例与医疗相关或环境损伤有关。36例(80%)在接受中位6个月抗菌方案后治愈,22例(55%)同时接受手术。作者提出超过6个月的抗菌治疗方案并考虑手术和定期再评估。
要点
- 肺外脓肿分枝杆菌感染主要累及免疫功能正常者,多发生于损伤后。
- 45例中36例(80%)治愈,接受中位6个月抗菌治疗,22例(55%)同时手术。
- 作者提出超过6个月的抗菌方案,并考虑手术及定期再评估。
核心结论
- 肺外脓肿分枝杆菌感染主要影响免疫功能正常者且多发生于损伤后,结局良好。
- 作者提出超过6个月的抗菌治疗方案,并考虑手术和定期患者再评估。
研究设计与样本
- 回顾性分析法国2012-2020年连续微生物学确诊的肺外脓肿分枝杆菌感染病例,共45例。
- 病例包括14例骨与关节感染、10例皮肤软组织感染和8例淋巴结感染。
主要发现
- 45例中62%无报告免疫缺陷。
- 27例肺外脓肿分枝杆菌感染发生于医疗相关(44%)或环境(16%)损伤后。
- 45株分离株中25株为脓肿亚种、10株为博莱蒂亚种、9株为马赛亚种,1株未鉴定。
- 36例(80%)治愈,接受中位6个月抗菌方案,其中22例(55%)同时手术。
- 4例死亡,5例失访。
临床怎么用
- 作者提出超过6个月的抗菌治疗方案,并考虑手术和定期患者再评估。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mycobacterium abscessus infection is challenging to treat. Extrapulmonary M. abscessus infections (EP-MAB) are less common than pulmonary M. abscessus infections. To evaluate treatment regimens, we retrospectively analyzed consecutive microbiologically confirmed EP-MAB cases diagnosed in France during 2012-2020. We studied 45 patients with EP-MAB, including 14 bone and joint infections, 10 skin and soft tissue infections, and 8 lymph node infections. Most (62%) patients had no reported immunodeficiency. In 27 patients, EP-MAB followed healthcare-associated (44%) or environmental (16%) injuries. Of the 45 isolates, 25 were subspecies abscessus, 10 bolletii, and 9 massiliense; 1 was unidentified. Cure was achieved for 36 (80%) patients who received a median antimicrobial regimen of 6 months; 22 (55%) also underwent surgery. Four patients died, and 5 were unavailable for follow-up. EP-MAB predominantly affects immunocompetent patients after an injury; outcomes are favorable. We propose a >6-month regimen of antimicrobial therapy with consideration for surgery and regular patient reassessment.
引用
- Heid-Picard B, Mougari F, Pouvaret A, et al. Extrapulmonary Mycobacterium abscessus Infections, France, 2012-20201. Emerg Infect Dis. 2024. PMID: 39447147. doi:10.3201/eid3011.240459
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。